Ground News

News from Pipelinereview

Stay current with all the latest and breaking news from Pipelinereview. Compare headlines and media bias behind news outlets on stories breaking today.

Ground News has come across 475 headlines reported on by Pipelinereview during the past 3 months.

Ground News rates Pipelinereview’s media bias as . . Ground News is unable to assign a bias rating and does not have ratings available from Ad Fontes Media, All Sides, and Media Bias/Fact Check.

Pipelinereview’s factuality rating is Unknown. Ground News calculates this rating using a combination of the fact and reliability ratings from Ad Fontes Media and Media Bias/Fact Check.

Information about Pipelinereview

Where is Pipelinereview located?Pipelinereview's Website

Media Bias Ratings

Do you diasgree?

Edit bias

Learn more about Media Bias Ratings.

Factuality

Learn more about Factuality Ratings

Reveal Factuality Ratings by upgrading to a Premium account.

Tap Upgrade to explore subscription options to meet all your reading needs.

Ownership

Learn more about Ownership categories

Reveal Ownership Data by upgrading to a Vantage account.

Tap Upgrade to explore subscription options to meet all your reading needs.

Top Pipelinereview News

Diabetes · United States

News from Pipelinereview

News from Pipelinereview

Information about Pipelinereview

Media Bias Ratings

Factuality

Ownership

Top Pipelinereview News

FDA OKs First Rapid-Acting Insulin Biosimilar for Diabetes

Johnson & Johnson halts late-stage E.coli vaccine trial after poor results

FDA approves more broadly protective meningococcal vaccine

Similar News Topics

Topics Most Covered by pipelinereview

Sources Covering Similar Topics

Breaking News Topics Related to Pipelinereview

News from Pipelinereview

Information about Pipelinereview

Media Bias Ratings

Factuality

Ownership

Breaking News Topics Related to Pipelinereview

Similar News Topics

Top Pipelinereview News

FDA OKs First Rapid-Acting Insulin Biosimilar for Diabetes

Johnson & Johnson halts late-stage E.coli vaccine trial after poor results

FDA approves more broadly protective meningococcal vaccine

European Commission Approves Belzutifan for VHL Disease–Associated Tumors, Advanced ccRCC

FDA sets June date for Gilead's twice-yearly HIV PrEP

Outstanding antitumor activity of first-in-class and so far best-in-class PD-1xVEGF bispecific antibody opens up plenty of opportunities for business deals and better followers - Pipelinereview

Celltrion to buy back $69 mil. of stocks for enhanced shareholder value

InnoCare Pharma receives approval for CLL/SLL combination therapy trial in China

LimmaTech Vaccinates First Participants in Phase 1 Study of Staphylococcus aureus Vaccine Candidate LBT-SA7 - Pipelinereview

Formycon announces decision on Phase III trial with FYB206 and provides update on potential need to adjust the valuation of FYB202 and FYB201 - Pipelinereview

New Data Demonstrated Best-in-Class Potential for Casdatifan, a HIF-2a Inhibitor, in Patients with Metastatic Kidney Cancer - Pipelinereview